What the FDA labels say about taking them together
Clobazam and flumazenil
Clobazam's FDA label of March 12, 2024 names flumazenil in its warnings and precautions section; flumazenil's label does not name clobazam itself but warns about its class (Benzodiazepines). The clobazam label: “Abrupt discontinuation or rapid dosage reduction of ONFI after continued use, or administration of flumazenil may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures).”
Check it at the source: the clobazam FDA label on DailyMed (effective March 12, 2024, Lundbeck Pharmaceuticals LLC); the flumazenil FDA label on DailyMed (effective June 21, 2024, Hikma Pharmaceuticals USA Inc.).
What does the clobazam label say about flumazenil?
Clobazam label, warnings and precautionsAbrupt discontinuation or rapid dosage reduction of ONFI after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence ( 9.3 )].
Source: FDA drug label (Sympazan, NDA210833), Aquestive Therapeutics, effective December 1, 2025 (SPL set 5e3d8fcb-aa7d-4822-88fc-4f06264c3242), via openFDA
Source: FDA drug label (Onfi), Lundbeck Pharmaceuticals LLC, effective March 12, 2024 (SPL set de03bd69-2dca-459c-93b4-541fd3e9571c), via openFDA; the full label on DailyMed
What does the flumazenil label say about clobazam?
Flumazenil's label does not name clobazam itself; it warns about its class (Benzodiazepines):
Flumazenil label, contraindicationsCONTRAINDICATIONS Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS ).
Flumazenil label, boxed warningTHESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE.
Source: FDA drug label (Flumazenil), Hikma Pharmaceuticals USA Inc., effective June 21, 2024 (SPL set 436f5616-9626-4b6a-9deb-2986444179d0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clobazam | Flumazenil | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.243 per tablet 10 mg tablet | $1.18 per mL 0.5 mg/5 mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once